Tags

Type your tag names separated by a space and hit enter

HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.
Transplantation 2014; 97(4):419-25T

Abstract

BACKGROUND

Dysglycemia and dyslipidemia are important metabolic complications of organ transplantation. Statins are widely used to control dyslipidemia; however, long-term use of statins is related to diabetes mellitus (DM) and impaired fasting glucose (IFG). The aim of this study was to evaluate the influence of statins on the development of dysglycemia (IFG and/or DM) in renal allograft recipients.

METHODS

A total of 394 patients without previously known DM or IFG who underwent kidney transplantation were enrolled. Patients were grouped into the two groups according to the use of statin (control, n=149; statin, n=245). The major statins used were fluvastatin (80 mg/d, n=134) and atorvastatin (20 mg/d, n=111). We compared the incidence of IFG or DM during the follow-up period.

RESULTS

The incidence of IFG was higher in the statin group than that in the control group (28.6% vs. 8.7%, P<0.001). The incidence of dysglycemia was significantly higher in the statin group (40.0% vs. 15.4%, P=0.001). Time to development of dysglycemia after transplantation was shorter in the statin group than in the control group (38.8±29.7 vs. 47.2±23.3 months, P=0.002). Statin use was associated with an increased risk for dysglycemia after adjustment for age, sex, body mass index, hypertension, cholesterol levels, hepatitis C infection, and type of immunosuppressant (hazard ratio=3.08, 95% confidence interval=1.91-4.98). The dysglycemic effect was more profound in the patients who used atorvastatin than in those who used fluvastatin (hazard ratio=2.21, 95% confidence interval=1.02-4.76).

CONCLUSION

Statin treatment is associated with an elevation in fasting plasma glucose and in the development of dysglycemia in renal allograft recipients.

Authors+Show Affiliations

1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. 2 Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. 3 Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea. 4 Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea. 5 Department of Transplantation Surgery Yonsei University Health System, Seoul, Korea. 6 Address correspondence to: Eun Seok Kang, M.D., Ph.D., Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-Ku, Seoul, 120-752, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24285338

Citation

Choe, Eun Yeong, et al. "HMG CoA Reductase Inhibitor Treatment Induces Dysglycemia in Renal Allograft Recipients." Transplantation, vol. 97, no. 4, 2014, pp. 419-25.
Choe EY, Wang HJ, Kwon O, et al. HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients. Transplantation. 2014;97(4):419-25.
Choe, E. Y., Wang, H. J., Kwon, O., Cho, Y., Huh, K. H., Kim, M. S., ... Kang, E. S. (2014). HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients. Transplantation, 97(4), pp. 419-25. doi:10.1097/01.TP.0000437427.04733.ad.
Choe EY, et al. HMG CoA Reductase Inhibitor Treatment Induces Dysglycemia in Renal Allograft Recipients. Transplantation. 2014 Feb 27;97(4):419-25. PubMed PMID: 24285338.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients. AU - Choe,Eun Yeong, AU - Wang,Hye Jin, AU - Kwon,Obin, AU - Cho,Yongin, AU - Huh,Kyu Ha, AU - Kim,Myoung Soo, AU - Kim,Yu Seun, AU - Ahn,Chul Woo, AU - Cha,Bong Soo, AU - Lee,Hyun Chul, AU - Kang,Eun Seok, PY - 2013/11/29/entrez PY - 2013/11/29/pubmed PY - 2014/4/18/medline SP - 419 EP - 25 JF - Transplantation JO - Transplantation VL - 97 IS - 4 N2 - BACKGROUND: Dysglycemia and dyslipidemia are important metabolic complications of organ transplantation. Statins are widely used to control dyslipidemia; however, long-term use of statins is related to diabetes mellitus (DM) and impaired fasting glucose (IFG). The aim of this study was to evaluate the influence of statins on the development of dysglycemia (IFG and/or DM) in renal allograft recipients. METHODS: A total of 394 patients without previously known DM or IFG who underwent kidney transplantation were enrolled. Patients were grouped into the two groups according to the use of statin (control, n=149; statin, n=245). The major statins used were fluvastatin (80 mg/d, n=134) and atorvastatin (20 mg/d, n=111). We compared the incidence of IFG or DM during the follow-up period. RESULTS: The incidence of IFG was higher in the statin group than that in the control group (28.6% vs. 8.7%, P<0.001). The incidence of dysglycemia was significantly higher in the statin group (40.0% vs. 15.4%, P=0.001). Time to development of dysglycemia after transplantation was shorter in the statin group than in the control group (38.8±29.7 vs. 47.2±23.3 months, P=0.002). Statin use was associated with an increased risk for dysglycemia after adjustment for age, sex, body mass index, hypertension, cholesterol levels, hepatitis C infection, and type of immunosuppressant (hazard ratio=3.08, 95% confidence interval=1.91-4.98). The dysglycemic effect was more profound in the patients who used atorvastatin than in those who used fluvastatin (hazard ratio=2.21, 95% confidence interval=1.02-4.76). CONCLUSION: Statin treatment is associated with an elevation in fasting plasma glucose and in the development of dysglycemia in renal allograft recipients. SN - 1534-6080 UR - https://www.unboundmedicine.com/medline/citation/24285338/HMG_CoA_reductase_inhibitor_treatment_induces_dysglycemia_in_renal_allograft_recipients_ L2 - http://dx.doi.org/10.1097/01.TP.0000437427.04733.ad DB - PRIME DP - Unbound Medicine ER -